James talks with the CEO and founder of mindbloom CEO Dylan Beynon about how his intimate familiarity with mental illness was in many ways the catalyst of his drive for success, and how experimenting with MDMA 11 years ago ultimately led him to the forefront of the research and legalization of psychedelics. James and Dylan discuss the evolving perception of psychedelics, both in general and as a legitimate means of psychotherapy, and some of the specific medications and their corresponding encouraging results in treating various psychological ailments.


Harvard Mental Illness Study

The Information Pathology by James Beshara

Mental Weatlh by James Beshara

Drug Harm Scale

About your host, James: James Beshara is a founder, investor, advisor, author, podcaster, and encourager based in Los Angeles, California. James has created startups for the last 12 years, selling one (Tilt, acquired by Airbnb), and invested in a few multi-billion dollar startups to date. He has spoken at places such as Y-Combinator, Harvard Business School, Stanford University, TechCrunch Disrupt, and has been featured in outlets like the New York Times, the Wall Street Journal, Fortune Magazine, and Time Magazine. He’s been featured in Forbes, Time, and Inc Magazine’s “30 Under 30” lists and advises startups all around the world. All of this is his “above the line” version of his background. Hear the other 90% of the story in the intro episode of Below The Line.

You can email James questions directly at [email protected] or follow us on Twitter @ — “Below the Line with James Beshara" is brought to you by Straight Up Podcasts LLC.

Podden och tillhörande omslagsbild på den här sidan tillhör James Beshara. Innehållet i podden är skapat av James Beshara och inte av, eller tillsammans med, Poddtoppen.